Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL529510 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL204687 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL3682796 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9109080 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692462 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL663145 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692471 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL663144 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL29391563 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL29253571 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558956-B1 | N-CYCLOBUTYL-THIAZOL-5-CARBOXAMIDES WITH NEMATICIDAL ACTIVITY | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200087271-A1 | N-CYCLOBUTYL-THIAZOL-5-CARBOXAMIDES WITH NEMATICIDAL ACTIVITY | SYNGENTA PARTICIPATIONS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| EP-3558956-A1 | N-CYCLOBUTYL-THIAZOL-5-CARBOXAMIDES WITH NEMATICIDAL ACTIVITY | Syngenta Participations AG (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-3421455-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018114657-A1 | N-CYCLOBUTYL-THIAZOL-5-CARBOXAMIDES WITH NEMATICIDAL ACTIVITY | SYNGENTA PARTICIPATIONS AG (CH) | 2018-06-28 | — | — | WO | disclosed |
| EP-3319941-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | SpecGx, LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3166923-A1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | Mallinckrodt LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2017044043-A1 | PROCESS FOR DIRECT AMIDATION OF AMINES VIA RH(I)-CATALYZED ADDITION OF BOROXINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017011231-A1 | A TWO-STEP PROCESS FOR PREPARING 3-SUBSTITUTED PHENYLALKYLAMINES | MALLINCKRODT LLC (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-3049396-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INDANYLOXYDIHYDROBENZOFURANYL ACETIC ACID DERIVATIVES AS GPR40 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2016-08-03 | — | — | EP | disclosed |
| EP-1320518-A2 | PREPARATION OF ENANTIOMERICALLY-ENRICHED CYCLOPROPYLALANINE DERIVATIVES | EASTMAN CHEMICAL COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2003014061-A1 | METHOD FOR THE PRODUCTION OF AMINES BY REDUCTIVE AMINATION OF CARBONYL COMPOUNDS UNDER TRANSFER-HYDROGENATION CONDITIONS | DEGUSSA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| US-20020065417-A1 | Useful as ligands for metal catalysts for asymmetric reactions, in particular as rhodium complexes for asymmetric hydrogenation of enamide, itaconate, and alpha-ketoester compounds | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2002-05-30 | — | — | US | disclosed |
| US-20020049331-A1 | Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026750-A2 | PHOSPHINO-AMINOPHOSPHINES, CATALYST COMPLEXES AND ENANTIOSELECTIVE HYDROGENATION | EASTMAN CHEMICAL COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026695-A2 | PREPARATION OF ENANTIOMERICALLY-ENRICHED CYCLOPROPYLALANINE DERIVATIVES | EASTMAN CHEMICAL COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6316380-B1 | ONE TRANSITION METAL COMPOUND AND AT LEAST ONE N-HETEROCYCLIC CARBENE OR ITS PROTONATED SALT | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2001-11-13 | — | — | US | disclosed |
| WO-2001066248-A2 | C-C AND C-N COUPLING CATALYST COMPRISING TRANSITION METAL AND CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION (US) | 2001-09-13 | — | — | WO | disclosed |
| US-4621150-A | METAL PERHALATE OR SULFONATE OR COMPLEX; GLYCIDATE, 2-HYDROXY-3-BUTENOATE, EPOXIDE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0153692-A2 | Method for isomerization a glycidate derivative | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049331-A1 | Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates | AZI2, PTMS, GNMT | GPR3 3524/4885CA1 3877/4885CA2 2647/4885 |
| US-20200087271-A1 | N-CYCLOBUTYL-THIAZOL-5-CARBOXAMIDES WITH NEMATICIDAL ACTIVITY | TUBA3C, NIT2, TUBB | GPR3 908/4885CA1 2671/4885CA2 788/4885 |
| US-20020065417-A1 | Useful as ligands for metal catalysts for asymmetric reactions, in particular as rhodium complexes for asymmetric hydrogenation of enamide, itaconate, and alpha-ketoester compounds | NOTUM, WEE1, WEE2 | GPR3 2985/4885CA1 327/4885CA2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.